Introduction: Asymptomatic arrhythmias can have important therapeutic implications in certain patient populations, for example, atrial fibrillation in patients with prior ischemic stroke. We sought to compare the diagnostic yield of two commercially available monitoring systems with automated arrhythmia detection algorithms.
constitute human research. We queried the BioTelemetry database retrospectively for the 8-month period (January 1, 2016-August 31, 2016) to evaluate data for every MCOT TM and AT-LER device with analyzable data during this timeframe. The 8-month database sample time window was chosen as a representative sample of recent patients from our entire database with no selection restrictions applied. All information lacked specific patient-related data other than age and gender; we stratified the resulting cohort based on these factors as both are associated with arrhythmia occurrence.
The MCOT TM device consists of a sensor with three leads providing two EKG channels for analysis by the monitor, which is a cell phonesized device communicating wirelessly with the sensor. The monitor contains embedded EKG analysis algorithms that analyze every heartbeat received from the sensor. The EKG signal is analyzed for threshold triggers related to rate, rhythm irregularity, QRS morphology, and p-wave analysis. When trigger thresholds are met, the monitor wirelessly sends representative arrhythmia diagnostic strips to an independent diagnostic testing facility (IDTF), which is staffed continuously, for further adjudication by monitoring center-trained technicians who also generate daily and end of service summary reports for final physician approval. If the arrhythmia characteristics meet notification criteria established for that patient, then the designated physician, and in emergency situations the patient/family, is notified. The device is prescribed for up to 30 days and has unlimited memory capacity due to its wireless connectivity. Specific timeframe data can be searched during the monitoring period and EKG strips for any time period can be examined. This device type also provides atrial fibrillation burden, heart rate trend data calculations, and can send unlimited patient-triggered events.
The AT-LER device has single or two EKG channel functionality and uses a rate and rhythm regularity detection algorithm to automatically trigger for arrhythmias. The device has finite memory storage for autotriggered events, comprising a total of five recordings of 90 seconds each (60 seconds predetection and 30 seconds postdetection).
The device reserves memory to receive a patient-initiated event as a sixth stored event. The device lacks wireless connectivity capability and the patient is required to transmit events via landline telephone.
Technicians review each patient data transmission subsequently generating reports for physician review and final interpretation. Failure to transmit data in a timely fashion can result in failing to retain future, newer events due to the limited memory capacity of the device. Since this device category captures only specific arrhythmia events, it lacks the capability to provide additional information on triggered events and also lacks the ability to search for EKG tracings during specific timeframes. This device type cannot determine arrhythmia offsets and as a result atrial fibrillation burden cannot be calculated. Notifications are also called to physicians when qualifying events are received by the IDTF based on arrhythmia criteria established for each patient with this device. Events can also be triggered by patient initiation but limited memory in the AT-LER device may restrict the number of events that can be recorded.
For each device type, analysis of diagnostic yield, mean time to first diagnosis, patient age and patient gender, and patient diagnostic codes were determined for the diagnoses of asymptomatic (devicetriggered) atrial fibrillation (any duration), bradycardia (ventricular rate ≤ 40 bpm), ventricular pause (≥ 3 seconds), supraventricular tachycardia (≥ 6 consecutive supraventricular beats), and ventricular tachycardia (≥ 4 consecutive premature ventricular contractions).
These arrhythmias were chosen as each device detects these arrhythmias based on triggers in the device algorithm for the parameters noted. The top 10 primary diagnostic codes chosen by physicians who ordered each device were determined from the database. Arrhythmia diagnoses were made by the embedded algorithms in each device type with subsequent independent confirmation or rejection by independent diagnostic testing facility trained technicians with ultimate adjudication made by independent physicians. The Cochran-MantelHaenszel procedure 1 was used to represent weighted average statistical comparisons of device performance for each decade of age and for each gender. P-values and 95% confidence intervals of each ratio of events across all demographic groups were calculated.
RESULTS
From the 8-month analysis period, data from 69,977 patients prescribed MCOT TM and 8,513 patients prescribed AT-LERs without wireless capability were examined. MCOT TM patients consisted of 43.1% males and 56.9% females, while the AT-LER device patients were composed of 38.0% males and 62.0% females. The same top 10 primary diagnostic codes are represented in differing proportions between device groups with the same 10 codes comprising 89% of MCOT TM patients and 87.8% of AT-LER patients (Tables 1 and 2 ).
Prescription length averaged 19.9 days (median 20 days) for patients monitored by MCOT TM and averaged 27.4 days (median 30 days) for patients monitored by an AT-LER device. Of note is that, starting with the second decade of life, the mean age for male and female patients within each decade of age varies between devices by no more than 1 year.
MCOT TM patients had significantly higher diagnostic yields for all five asymptomatic arrhythmias examined compared to the AT-LER despite a 7.5 day shorter average prescription length for MCOT TM patients. Examination of these diagnostic yields of each device for each arrhythmia reveals that MCOT TM has a 128% higher diagnostic yield for AF, a 54% higher diagnostic yield for bradycardia, a 17% higher diagnostic yield for ventricular pause, an 80% higher diagnostic yield for supraventricular tachycardia, and a 222.2% higher diagnostic yield for ventricular tachycardia than the AT-LER (Table 3 ).
The mean time to diagnosis for each asymptomatic arrhythmia evaluated was shorter for patients monitored with MCOT TM compared to patients monitored with an AT-LER device. The MCOT TM device needed 1.9 fewer days to detect AF, 1.0 day less to detect bradycardia, 6.7 fewer days to detect ventricular pauses, 2.5 fewer days to detect supraventricular tachycardia, and 3.8 fewer days to detect ventricular tachycardia than the AT-LER (Table 3) .
DISCUSSION
The main findings of our study include: 
LIMITATIONS
The choice of a specific monitoring technology was made by the ordering physician based on personal or patient-related preferences. Despite the bias inherent in nonrandomized designs, the large cohort included may mitigate the impact of selection bias to some degree.
The BioTelemetry database contains no information on patient comorbid conditions so the distribution of comorbidities between patients using the two devices is unknown. Patients under 40 years of age were underrepresented in our cohort, and thus our results may be less generalizable to this cohort.
While both devices have the capability of recording patient initiated events generated by patient interaction as the result of symptoms, we cannot exclude that knowledge of the autotrigger functionality may cause some patients to forgo patient initiation to record events.
Since both devices have this autotrigger functionality, it is likely that the action by some patients to avoid patient initiation to record symptomatic events may lead to the possible inclusion of some symptomatic arrhythmias with those arrhythmias that we have defined as asymptomatic (device-triggered).
Transmission of data to the monitoring center may be adversely affected by limited wireless accessibility (MCOT TM ) and landline connection quality (AT-LER).
Despite meticulous review of EKG data by certified EKG technicians and over-reading physicians, the possibility of arrhythmia interpretation errors may exist. Technician participation is inherent in both the collection and interpretation of the primary monitoring data.
CONCLUSION
In a large patient cohort with standard diagnostic indications for cardiac monitoring, MCOT TM demonstrated a higher diagnostic yield and a shorter time to arrhythmia diagnosis compared to AT-LERs.
Wireless connectivity may serve to enhance asymptomatic arrhythmia detection with MCOT TM compared to nonwireless devices by improving patient compliance in data retrieval. This study serves to further inform the provider's decision in choosing a specific monitoring device for their patient.
